Business Context and Reporting Period
This Form 8-K, dated May 31, 2022, reports on Becton, Dickinson and Company (BD) following the completion of the separation and distribution of its Diabetes Care business (Embecta Corp.) on April 1, 2022. The filing provides unaudited recast historical financial information for the three months ended March 31, 2022, and 2021, presenting the former Diabetes Care business as discontinued operations to establish a standalone baseline for continuing operations.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references Exhibit 99.1 for the detailed unaudited recast financial information and non-GAAP measures. The document outlines the methodology for calculating these metrics, specifically noting adjustments for "specified items" such as purchase accounting, integration costs, restructuring, litigation, and European regulatory initiative costs.
Material Changes and Adjustments
- Structural Change: The primary material change is the spin-off of the Diabetes Care business into Embecta Corp., requiring the recasting of historical financials to exclude this segment as discontinued operations.
- Non-GAAP Adjustments: Management adjusts financial results to exclude European regulatory initiative-related costs (compliance with EU Medical Device and In Vitro Diagnostic Regulations). These costs, recorded in Cost of products sold and R&D, are considered one-off and duplicative of prior costs.
- Other Adjustments: Non-GAAP measures also exclude transaction gains/losses, investment gains/losses, asset impairments, and debt extinguishment impacts.
Management Commentary and Risks
Management states that non-GAAP measures are used to help investors understand underlying operational trends and year-over-year performance by removing items that affect comparability. However, the filing includes a caution that these non-GAAP measures are not replacements for GAAP results and may differ from similar measures used by other companies. Management emphasizes that excluded items can materially impact net income and cash flows under GAAP. The filing explicitly states that the information contained herein is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited recast financial figures for the three months ended March 31, 2022, and 2021.
- Verify the reconciliation between GAAP and non-GAAP measures to understand the magnitude of excluded "specified items."
- Confirm the treatment of the Diabetes Care business as discontinued operations in future reporting periods.
- Assess the impact of European regulatory compliance costs on future operating expenses, as these are currently excluded from non-GAAP metrics.